SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

03 May 2024 Evaluate
The sales is pegged at Rs. 939.31 millions for the March 2024 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 1194.06 millions during the year-ago period.A big decline of -48.95% was reported for the quarter ended March 2024 to Rs. 82.47  millions from Rs. 161.54 millions of corresponding previous quarter.The company reported a good operating profit of 187.25 millions compared to 161.86 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 939.31 1194.06 -21.33 3786.77 4030.44 -6.05 3786.77 4030.44 -6.05
Other Income 45.27 7.83 478.16 75.08 56.78 32.23 75.08 56.78 32.23
PBIDT 187.25 161.86 15.69 743.73 603.56 23.22 743.73 603.56 23.22
Interest 2.18 31.79 -93.14 65.07 83.84 -22.39 65.07 83.84 -22.39
PBDT 185.07 94.20 96.46 678.66 483.85 40.26 678.66 483.85 40.26
Depreciation 62.31 25.30 146.28 256.01 95.54 167.96 256.01 95.54 167.96
PBT 122.76 68.90 78.17 422.65 388.31 8.84 422.65 388.31 8.84
TAX 40.29 -92.64 -143.49 129.17 -16.34 -890.51 129.17 -16.34 -890.51
Deferred Tax 19.02 -48.04 -139.59 55.74 -35.93 -255.13 55.74 -35.93 -255.13
PAT 82.47 161.54 -48.95 293.48 404.65 -27.47 293.48 404.65 -27.47
Equity 233.92 221.65 5.54 233.92 221.65 5.54 233.92 221.65 5.54
PBIDTM(%) 19.93 13.56 47.06 19.64 14.98 31.15 19.64 14.98 31.15

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×